Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards

Tris Pharma Issues Recall of Infants’ Concentrated Oral Suspension Ibuprofen

By Tris Pharma, Inc. | December 5, 2018

Tris Pharma, Inc. has voluntarily recalled three lots of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, to the retail level. The recalled lots of the product have been found to potentially have higher concentrations of ibuprofen.

There is a remote possibility that infants, who may be more susceptible to a higher potency level of drug, might be more vulnerable to permanent NSAID-associated renal injury.

Adverse effects that may be experienced are nausea, vomiting, epigastric pain, or more rarely, diarrhea. Tinnitus, headache, and gastrointestinal bleeding are also possible adverse effects. To date, Tris Pharma, Inc. has not received any reports of adverse events related to the lots of product that are the subject of the recall.

The product is used as a pain reliever/fever reducer and was packaged in 0.5 oz. bottles for the recalled lots listed below:

NDC LOT EXPIRATION DESCRIPTION  COMPANY
49035-125-23 00717009A

00717015A

00717024A

02/19

04/19

08/19

Equate: Infants’

Ibuprofen

Concentrated Oral

Suspension,

USP (NSAID), 50

mg per 1.25 mL,

0.5 oz. bottle

Wal-Mart

Stores Inc

59779-925-23 00717024A 08/19 CVS Health:

Infants’ Ibuprofen

Concentrated Oral

Suspension,

USP (NSAID), 50

mg per 1.25 mL,

0.5 oz. bottle

CVS

Pharmacy

55319-250-23 00717024A 08/19 Family Wellness:

Infants’ Ibuprofen

Concentrated Oral

Suspension,

USP (NSAID), 50

mg per 1.25 mL,

0.5 oz. bottle

Family Dollar

Services Inc.

Tris Pharma, Inc. sold the affected lots of Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL to one customer, which distributed the lots into the US market. Tris Pharma, Inc. has notified its customer by urgent recall notice and is arranging for the return of the recalled product.

Wholesalers and retailers of the product should stop further distribution of the affected lots of Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, which are being recalled.

Consumers with questions regarding this recall can contact Tris Customer Service at 732-940-0358 (Monday through Friday, 8:00am ET- 5:00pm PT) or via email at Customer Service Email.  Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

(Source: Tris Pharma, Inc.)

Related Articles Read More >

Torrent Pharmaceuticals Issues Voluntary Nationwide Recall of Losartan Potassium Tablets
Latex Hazard Leads to Recall of Certain Dyural-40 and Dyural-80 Convenience Kits
Pfizer Issues Voluntary Nationwide Recall of Six Lots of Thermacare Heatwraps
Mylan Initiates Nationwide Recall of 15 Lots of Valsartan Tablets

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Pharmaceutical Processing World
  • Enews Signup
  • Contact Us
  • R&D World
  • Drug Discovery & Development

Copyright © 2019 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards